ClinicalTrials. gov Interventional Model Description: This study is a randomized, placebo-controlled design with a 2:1 allocation of anakinra or placebo for the first 42 continuous days After day 42, a second placebo-controlled period will begin for an additional 42 days
A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear The purpose of this study is to determine if Anakinra (an interleukin-1 receptor antagonist) can improve hearing thresholds in those patients with Autoimmune Inner Ear Disease (AIED) that did not respond to oral steroid therapy for a sudden decline in hearing
Cochlear blood flow in response to dilating agents The drugs, their MW, concentrations and most widely accepted mode of action are given in Table I All the animals tolerated the anesthesia and surgery